{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T05:23:48Z","timestamp":1731043428480,"version":"3.28.0"},"reference-count":27,"publisher":"Texas Heart Institute Journal","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"abstract":"Abstract<\/jats:title>\n \n Background:<\/jats:title>\n This study compared the safety and effectiveness of paclitaxel\/cilostazol\u2013eluting Cilotax stents with those of everolimus-eluting stents in patients with acute myocardial infarction. Real-world data from the Korea Acute Myocardial Infarction Registry were examined.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n A total of 5,472 patients with acute myocardial infarction underwent percutaneous coronary intervention with Cilotax stents (n = 212) or everolimus-eluting stents (n = 5,260). The primary end point was the 3-year rate of target lesion failure. The other end points were major adverse cardiovascular events (a composite of cardiac death, target vessel myocardial infarction, and ischemia-driven target lesion revascularization), target vessel revascularization, and stent thrombosis. A propensity score matching analysis was performed to adjust for potential confounders by using a logistic regression model; propensity score matching generated 2 well-balanced groups (Cilotax group, n = 180; everolimus-eluting stents group, n = 170; N = 350). After propensity score matching, baseline clinical characteristics were similar between the groups.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n After percutaneous coronary intervention, compared with the everolimus-eluting stents group, the Cilotax group more often had major adverse cardiovascular events (24.1% vs 18.5%; P<\/jats:italic> = .042), myocardial infarction (8.0% vs 3.2%; P<\/jats:italic> < .001), target lesion revascularization (8.0% vs 2.6%; P<\/jats:italic> < .001), target vessel revascularization (11.3% vs 4.5%; P<\/jats:italic> < .001), and stent thrombosis (4.7% vs 0.5%; P<\/jats:italic> < .001) before matching. Even after matching, the Cilotax group had more frequent target lesion revascularization (9.4% vs 2.9%; P<\/jats:italic> = .22) and stent thrombosis (5.6% vs 1.2%; P<\/jats:italic> = .34).<\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n In patients with acute myocardial infarction who underwent percutaneous coronary intervention, use of the Cilotax stent was associated with higher rates of target lesion revascularization, target vessel revascularization, and stent thrombosis than were everolimus-eluting stents. Use of the Cilotax dual drugeluting stent should be avoided in the treatment of myocardial infarction.<\/jats:p>\n <\/jats:sec>","DOI":"10.14503\/thij-23-8271","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T09:15:06Z","timestamp":1714468506000},"source":"Crossref","is-referenced-by-count":0,"title":["Three-Year Clinical Outcomes With the Cilotax Dual Drug-Eluting Stent vs Everolimus-Eluting Stents in Patients With Acute Myocardial Infarction"],"prefix":"10.14503","volume":"51","author":[{"given":"HyeYon","family":"Yu","sequence":"first","affiliation":[{"name":"School of Nursing, College of Medicine, Soonchunhyang University, Asan, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jihun","family":"Ahn","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Daejeon Eulji Medical Center, Eulji University College of Medicine, Daejeon, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byoung Geol","family":"Choi","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, Korea University Guro Hospital, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soohyung","family":"Park","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, Korea University Guro Hospital, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong Oh","family":"Kang","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, Korea University Guro Hospital, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheol Ung","family":"Choi","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, Korea University Guro Hospital, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Woon","family":"Rha","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, Korea University Guro Hospital, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myung Ho","family":"Jeong","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Chonnam National University Hospital, Gwangju, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5628","reference":[{"issue":"2","key":"b1","series-title":"J Interv Cardiol","first-page":"147","article-title":"Comparisons of everolimus and paclitaxel-eluting stents in patients with acute myocardial infarction","volume":"28","author":"Chen\n KY","year":"2015","unstructured":"Chen\n KY\n , RhaSW, LiYJ, et al; Korea Acute Myocardial Infarction Registry Investigators. Comparisons of everolimus and paclitaxel-eluting stents in patients with acute myocardial infarction. J Interv Cardiol. 2015;28(2):147-156. doi:10.1111\/joic.12187"},{"issue":"6","key":"b2","series-title":"Catheter Cardiovasc Interv","first-page":"869","article-title":"Impact of advanced age on the safety and effectiveness of paclitaxel-eluting stent implantation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: the HORIZONS-AMI trial","volume":"82","author":"Dudek\n D","year":"2013","unstructured":"Dudek\n D\n , MehranR, DziewierzA, et al.\n Impact of advanced age on the safety and effectiveness of paclitaxel-eluting stent implantation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: the HORIZONS-AMI trial. Catheter Cardiovasc Interv. 2013;82(6):869-877. doi:10.1002\/ccd.24813"},{"issue":"5","key":"b3","series-title":"Nat Rev Cardiol","first-page":"248","article-title":"New concepts in the design of drug-eluting coronary stents","volume":"10","author":"Garg\n S","year":"2013","unstructured":"Garg\n S\n , BourantasC, SerruysPW. New concepts in the design of drug-eluting coronary stents. Nat Rev Cardiol. 2013;10(5):248-260. doi:10.1038\/nrcardio.2013.13"},{"issue":"3","key":"b4","series-title":"Int J Cardiol","first-page":"1056","article-title":"Very late stent thrombosis in patients with first-generation drug-eluting stents: a systematic review of reported cases","volume":"177","author":"Franck\n C","year":"2014","unstructured":"Franck\n C\n , EisenbergMJ, DourianT, GrandiSM, FilionKB. Very late stent thrombosis in patients with first-generation drug-eluting stents: a systematic review of reported cases. Int J Cardiol. 2014;177(3):1056-1058. doi:10.1016\/j.ijcard.2014.11.030"},{"issue":"9","key":"b5","series-title":"J Invasive Cardiol","first-page":"413","article-title":"\u201cVery\u201d very late stent thrombosis: acute myocardial infarction from drug-eluting stent thrombosis more than 5 years after implantation","volume":"26","author":"Kaliyadan\n A","year":"2014","unstructured":"Kaliyadan\n A\n , SiuH, FischmanDL, et al.\n \u201cVery\u201d very late stent thrombosis: acute myocardial infarction from drug-eluting stent thrombosis more than 5 years after implantation. J Invasive Cardiol. 2014;26(9):413-416."},{"key":"b6","series-title":"J Interv Cardiol","first-page":"1710439","article-title":"Comparison of first-and second-generation drug-eluting stents in patients with acute myocardial infarction and prediabetes based on the hemoglobin A1c level","volume":"2020","author":"Kim\n YH","year":"2020","unstructured":"Kim\n YH\n , HerAY, JeongMH, et al.\n Comparison of first-and second-generation drug-eluting stents in patients with acute myocardial infarction and prediabetes based on the hemoglobin A1c level. J Interv Cardiol. 2020;2020:1710439. doi:10.1155\/2020\/1710439"},{"issue":"4","key":"b7","series-title":"Kardiol Pol","first-page":"493","article-title":"[Commentary to the article: Kedhi E, Joesoef KS, McFadden E et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet 2010; 375: 201-209]","volume":"68","author":"Sosnowski\n C","year":"2010","unstructured":"Sosnowski\n C\n \n . [Commentary to the article: Kedhi E, Joesoef KS, McFadden E et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet 2010; 375: 201-209]. Kardiol Pol. 2010;68(4):493-496; discussion 497-499."},{"issue":"12","key":"b8","series-title":"JACC Cardiovasc Interv","first-page":"1267","article-title":"Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients","volume":"6","author":"Tada\n T","year":"2013","unstructured":"Tada\n T\n , ByrneRA, SimunovicI, et al.\n Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients. JACC Cardiovasc Interv. 2013;6(12):1267-1274. doi:10.1016\/j.jcin.2013.06.015"},{"issue":"7","key":"b9","series-title":"Am J Cardiol","first-page":"990","article-title":"Comparison of dual drug-eluting Cilotax stent and paclitaxel-eluting Taxus Liberte stent in native coronary artery lesions","volume":"107","author":"Lee\n CW","year":"2011","unstructured":"Lee\n CW\n , ParkDW, SeungKB, et al.\n Comparison of dual drug-eluting Cilotax stent and paclitaxel-eluting Taxus Liberte stent in native coronary artery lesions. Am J Cardiol. 2011;107(7):990-994. doi:10.1016\/j.amjcard.2010.11.021"},{"issue":"6","key":"b10","series-title":"Korean Circ J","first-page":"811","article-title":"Differences in the Korea Acute Myocardial Infarction Registry compared with western registries","volume":"47","author":"Sim\n DS","year":"2017","unstructured":"Sim\n DS\n , JeongMH. Differences in the Korea Acute Myocardial Infarction Registry compared with western registries. Korean Circ J. 2017;47(6):811-822. doi:10.4070\/kcj.2017.0027"},{"issue":"1","key":"b11","series-title":"Curr Cardiol Rev","first-page":"3","article-title":"Adherence to cardiac practice guidelines in the management of non-ST-elevation acute coronary syndromes: a systematic literature review","volume":"13","author":"Engel\n J","year":"2017","unstructured":"Engel\n J\n , DamenNL, van der WulpI, de BruijneMC, WagnerC. Adherence to cardiac practice guidelines in the management of non-ST-elevation acute coronary syndromes: a systematic literature review. Curr Cardiol Rev. 2017;13(1):3-27. doi:10.2174\/1573403x12666160504100025"},{"issue":"4","key":"b12","series-title":"Acta Cardiol Sin","first-page":"285","article-title":"2020 focused update of the 2012 guidelines of the Taiwan Society of Cardiology for the management of ST-segment elevation myocardial infarction","volume":"36","author":"Li\n YH","year":"2020","unstructured":"Li\n YH\n , LeeCH, HuangWC, et al.\n 2020 focused update of the 2012 guidelines of the Taiwan Society of Cardiology for the management of ST-segment elevation myocardial infarction. Acta Cardiol Sin. 2020;36(4):285-307. doi:10.6515\/ACS.202007_36(4).20200619A"},{"issue":"5","key":"b13","series-title":"Medicine (Baltimore)","article-title":"Is there any significant difference in stent thrombosis between sirolimus and paclitaxel eluting stents?: a systematic review and meta-analysis of randomized controlled trials","volume":"95","author":"Bundhun\n PK","year":"2016","unstructured":"Bundhun\n PK\n , WuZJ, ChenMH. Is there any significant difference in stent thrombosis between sirolimus and paclitaxel eluting stents?: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016;95(5):e2651. doi:10.1097\/MD.0000000000002651"},{"issue":"18","key":"b14","series-title":"N Engl J Med","first-page":"1663","article-title":"Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease","volume":"362","author":"Stone\n GW","year":"2010","unstructured":"Stone\n GW\n , RizviA, NewmanW, et al; SPIRIT IV Investigators. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med. 2010;362(18):1663-1674. doi:10.1056\/NEJMoa0910496"},{"issue":"10","key":"b15","series-title":"JACC Cardiovasc Interv","first-page":"1104","article-title":"Comparison of everolimus- and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: pooled results from the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) Trials","volume":"4","author":"Planer\n D","year":"2011","unstructured":"Planer\n D\n , SmitsPC, KereiakesDJ, et al.\n Comparison of everolimus- and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: pooled results from the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) Trials. JACC Cardiovasc Interv. 2011;4(10):1104-1115. doi:10.1016\/j.jcin.2011.06.018"},{"issue":"5","key":"b16","series-title":"J Am Coll Cardiol","first-page":"381","article-title":"Second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction. 1-year results of the randomized XAMI (XienceV Stent vs. Cypher Stent in Primary PCI for Acute Myocardial Infarction) trial","volume":"60","author":"Hofma\n SH","year":"2012","unstructured":"Hofma\n SH\n , BrouwerJ, VeldersMA, et al.\n Second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction. 1-year results of the randomized XAMI (XienceV Stent vs. Cypher Stent in Primary PCI for Acute Myocardial Infarction) trial. J Am Coll Cardiol. 2012;60(5):381-387. doi:10.1016\/j. jacc.2012.01.073"},{"issue":"10","key":"b17","series-title":"Am J Cardiol","first-page":"1370","article-title":"Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction","volume":"104","author":"Lee\n CW","year":"2009","unstructured":"Lee\n CW\n , ParkDW, LeeSH, et al; ZEST-AMI Investigators. Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. Am J Cardiol. 2009;104(10):1370-1376. doi:10.1016\/j.amjcard.2009.06.059"},{"issue":"8","key":"b18","series-title":"J Geriatr Cardiol","first-page":"523","article-title":"Five-year major clinical outcomes between first-generation and second-generation drug-eluting stents in acute myocardial infarction patients underwent percutaneous coronary intervention","volume":"15","author":"Kim\n YH","year":"2018","unstructured":"Kim\n YH\n , HerAY, RhaSW, et al.\n Five-year major clinical outcomes between first-generation and second-generation drug-eluting stents in acute myocardial infarction patients underwent percutaneous coronary intervention. J Geriatr Cardiol. 2018;15(8):523-533. doi:10.11909\/j.issn.1671-5411.2018.08.006"},{"issue":"9562","key":"b19","series-title":"Lancet","first-page":"667","article-title":"Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study","volume":"369","author":"Daemen\n J","year":"2007","unstructured":"Daemen\n J\n , WenaweserP, TsuchidaK, et al.\n Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369(9562):667-678. doi:10.1016\/S0140-6736(07)60314-6"},{"issue":"18","key":"b20","series-title":"Eur Heart J","first-page":"2202","article-title":"A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study","volume":"29","author":"Angiolillo\n DJ","year":"2008","unstructured":"Angiolillo\n DJ\n , CapranzanoP, GotoS, et al.\n A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Eur Heart J. 2008;29(18):2202-2211. doi:10.1093\/eurheartj\/ehn287"},{"issue":"1","key":"b21","series-title":"J Clin Med","first-page":"69","article-title":"Efficacy and safety of dual-drug-eluting stents for de novo coronary lesions in South Korea\u2014the effect trial","volume":"10","author":"Cha\n JJ","year":"2020","unstructured":"Cha\n JJ\n , KimGC, HurSH, et al.\n Efficacy and safety of dual-drug-eluting stents for de novo coronary lesions in South Korea\u2014the effect trial. J Clin Med. 2020;10(1):69. doi:10.3390\/jcm10010069"},{"issue":"5","key":"b22","series-title":"N Engl J Med","first-page":"483","article-title":"Coronary-artery stents","volume":"354","author":"Serruys\n PW","year":"2006","unstructured":"Serruys\n PW\n , KutrykMJB, OngATL. Coronary-artery stents. N Engl J Med. 2006;354(5):483-495. doi:10.1056\/NEJMra051091"},{"issue":"22","key":"b23","series-title":"Eur Heart J","first-page":"2685","article-title":"Stent thrombosis: who's guilty?","volume":"30","author":"Montalescot\n G","year":"2009","unstructured":"Montalescot\n G\n , HulotJS, ColletJP. Stent thrombosis: who's guilty?Eur Heart J. 2009;30(22):2685-2688. doi:10.1093\/eurheartj\/ehp436"},{"issue":"5","key":"b24","series-title":"Clin Ther","first-page":"1058","article-title":"A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation","volume":"19","author":"Kunishima\n T","year":"1997","unstructured":"Kunishima\n T\n , MushaH, EtoF, et al.\n A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation. Clin Ther. 1997;19(5):1058-1066. doi:10.1016\/s0149-2918(97)80058-6"},{"key":"b25","series-title":"Thrombosis","first-page":"956962","article-title":"Stent thrombosis: incidence, predictors and new technologies","volume":"2012","author":"Buchanan\n GL","year":"2012","unstructured":"Buchanan\n GL\n , BasavarajaiahS, ChieffoA. Stent thrombosis: incidence, predictors and new technologies. Thrombosis. 2012;2012:956962. doi:10.1155\/2012\/956962"},{"issue":"10","key":"b26","series-title":"JACC Cardiovasc Interv","first-page":"1057","article-title":"Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis","volume":"4","author":"Inoue\n T","year":"2011","unstructured":"Inoue\n T\n , CroceK, MorookaT, SakumaM, NodeK, SimonDI. Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis. JACC Cardiovasc Interv. 2011;4(10):1057-1066. doi:10.1016\/j.jcin.2011.05.025"},{"issue":"1","key":"b27","series-title":"J Control Release","first-page":"1","article-title":"Dual drug-eluting stent","volume":"159","author":"Park\n K","year":"2012","unstructured":"Park\n K\n \n . Dual drug-eluting stent. J Control Release. 2012;159(1):1. doi:10.1016\/j.jconrel.2012.03.019"}],"container-title":["Texas Heart Institute Journal"],"original-title":[],"link":[{"URL":"https:\/\/thij.kglmeridian.com\/view\/journals\/thij\/51\/1\/article-e238271.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/meridian.allenpress.com\/thij\/article-pdf\/doi\/10.14503\/THIJ-23-8271\/3410943\/i1526-6702-51-1-e238271.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thij.kglmeridian.com\/downloadpdf\/journals\/thij\/51\/1\/article-e238271.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thij.kglmeridian.com\/downloadpdf\/journals\/thij\/51\/1\/article-e238271.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T15:38:05Z","timestamp":1730993885000},"score":1,"resource":{"primary":{"URL":"https:\/\/thij.kglmeridian.com\/view\/journals\/thij\/51\/1\/article-e238271.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":27,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.14503\/thij-23-8271","relation":{},"ISSN":["1526-6702","0730-2347"],"issn-type":[{"type":"electronic","value":"1526-6702"},{"type":"print","value":"0730-2347"}],"subject":[],"published":{"date-parts":[[2024]]}}}